Trading on split-adjusted basis will begin at market open on July 29, 2025. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support its ...

Inside the packed auditorium of Government College for Women, M.A. Road, Srinagar, more than a hundred faculty members gathered Tuesday m ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to accelerate the clinical development of "T regulatory cell" therapies for the ...

With the signing of the Sunshine Genetics Act, Florida has positioned itself as a national leader in pediatric genetic ...

Rep. Ro Khanna (D-Calif.) has been one of the more nuanced Democratic critics of the tech sector during President Donald Trump’s second administration. Khanna, whose district covers Silicon Valley, ...

Investing.com -- Gain Therapeutics Inc (NASDAQ: GANX) stock fell 11% after the clinical-stage biotechnology company announced plans for an underwritten public offering of common stock and warrants to ...

There are all these drugs available, sitting in your local pharmacy, but they aren’t being used to treat all the conditions ...

Jeneen Interlandi, a domestic correspondent for Opinion and a staff writer at the magazine, writes frequently about public ...

Presented in collaboration with headline sponsor Old Mutual and metaverse partner UBU, the SingularityU South Africa Summit ...

From the internet to the ozone layer, AI to the human genome, UC scientists have turned federal research funding into history ...

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.

In April of that year, patients started appearing at hospitals in the industrial city of Sverdlovsk, now known as ...